Tango Therapeutics, Inc.
TNGX
$31.47
$1.334.41%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -100.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -100.00% | |||
| Cost of Revenue | 4.46% | 4.17% | |||
| Gross Profit | -4.46% | -239.59% | |||
| SG&A Expenses | 56.05% | 9.40% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 16.49% | 5.35% | |||
| Operating Income | -16.49% | -397.50% | |||
| Income Before Tax | -17.29% | -344.45% | |||
| Income Tax Expenses | 101.82% | -450.00% | |||
| Earnings from Continuing Operations | -17.46% | -343.95% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -17.46% | -343.95% | |||
| EBIT | -16.49% | -397.50% | |||
| EBITDA | -16.72% | -382.94% | |||
| EPS Basic | -7.64% | -305.80% | |||
| Normalized Basic EPS | -15.87% | -295.97% | |||
| EPS Diluted | -7.64% | -326.54% | |||
| Normalized Diluted EPS | -15.87% | -308.08% | |||
| Average Basic Shares Outstanding | 9.11% | 18.59% | |||
| Average Diluted Shares Outstanding | 9.11% | 11.72% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||